Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 million-$57 million from the previously reaffirmed $60 million-$62 million, signaling a significant downward revision. This investigation could impact investors who suffered losses due to the revenue shortfall and guidance cut. Investors are encouraged to contact Levi & Korsinsky for potential recovery options under federal securities laws.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...
Figma has achieved a 46% year-over-year revenue growth and improved its net dollar retention to 139%, showing resilience against fears of AI disruption. The company is transitioning to a usage-based pricing model and benefiting from AI trends, which ...
T. Rowe Price, a Dividend Aristocrat with 39 years of dividend growth, maintains a strong balance sheet and offers about a 5% dividend yield. However, the company is experiencing persistent net outflows and fee compression, which are structural chall...
In 2026, retirees aged 73 must take required minimum distributions (RMDs) from their 401(k) accounts, triggering significant tax bills. A retiree with $1.3 million in a 401(k) and $36,000 in Social Security could owe nearly $19,800 in combined federa...
